Get the Stockscreener App
9.05
2.58%
-0.24
Zenas Biopharma Inc stock is traded at $9.05, with a volume of 86,427.
It is down -2.58% in the last 24 hours and up +20.83% over the past month.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
See More
Previous Close:
$9.29
Open:
$9.21
24h Volume:
86,427
Relative Volume:
0.48
Market Cap:
$498.66M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-24.08%
1M Performance:
+20.83%
6M Performance:
-56.90%
1Y Performance:
+0.00%
1-Day Range:
$9.00
$9.8478
1-Week Range:
$8.51
$12.05
52-Week Range:
$5.83
$26.25
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Name
Zenas Biopharma Inc
Sector
Industry
Phone
857-271-2954
Address
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
9.05 | 498.66M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | Wedbush | Outperform |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
View All
Zenas Biopharma Inc Stock (ZBIO) Latest News
Cohen Milstein Continues Lead Plaintiff Search for Zenas - GlobeNewswire
Cohen Milstein Continues Lead Plaintiff Search for Zenas BioPharma (ZBIO) Securities Fraud Class Action Following Post-IPO Stock Decline - GlobeNewswire Inc.
Levi & Korsinsky Notifies Shareholders of Zenas BioPharma, Inc.(ZBIO) of a Class Action Lawsuit and an Upcoming Deadline - Morningstar
Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your RightsZBIO - ACCESS Newswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - ACCESS Newswire
Shareholders Who Lost Money on Zenas BioPharma, Inc. (ZBIO) Should Contact Levi & Korsinsky about Pending Class ActionZBIO - ACCESS Newswire
Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) Seeking Recovery for InvestorsContact The Gross Law Firm - PR Newswire
Zenas BioPharma, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your RightsZBIO - ACCESS Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
The Gross Law Firm Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 – ZBIO - TradingView
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
ZBIO Shareholders Have Opportunity to Lead Zenas BioPharma, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - PR Newswire
Levi & Korsinsky Notifies Shareholders of Zenas BioPharma, Inc. (ZBIO) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - StreetInsider
Shareholders that lost money on Zenas BioPharma, Inc.(ZBIO) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming DeadlinesZBIO - PR Newswire
ZBIO Stock Notice: Zenas BioPharma, Inc. Stockholders are Encouraged to Contact Shareholder ... - Bluefield Daily Telegraph
ZBIO Stock Notice: Zenas BioPharma, Inc. Stockholders are - GlobeNewswire
Cohen Milstein Reminds Zenas BioPharma (ZBIO) Investors of Opportunity to Lead Securities Fraud Suit - GlobeNewswire
Levi & Korsinsky Announces the Filing of a Securities Class - GlobeNewswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Zenas ... - Bluefield Daily Telegraph
ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Bullish Zenas BioPharma Insiders Loaded Up On US$2.11m Of Stock - simplywall.st
The Gross Law Firm Notifies Shareholders of Zenas BioPharma, Inc.(ZBIO) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire
Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Kors - GuruFocus
Zenas BioPharma, Inc. Sued for Securities Law Violations – - GlobeNewswire
Cohen Milstein Seeks Investors to Lead Suit to Hold Zenas BioPharma (ZBIO) Accountable for IPO-Related Fraud - GlobeNewswire
The Gross Law Firm Reminds Zenas BioPharma, Inc. Investors - GlobeNewswire
Zenas BioPharma, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your RightsZBIO - ACCESS Newswire
The Gross Law Firm Notifies Shareholders of Zenas BioPharma, Inc - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - StreetInsider
Robbins LLP Reminds ZBIO Stockholders with Large Losses to Contact the Law Firm for Information - Bluefield Daily Telegraph
Robbins LLP Reminds ZBIO Stockholders with Large Losses to - GlobeNewswire
Robbins LLP Reminds ZBIO Stockholders with Large Losses to Contact the Law Firm for Information on Leading the Zenas BioPharma, Inc. Class Action - TradingView
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Lawsuit Filed by The Rosen Law Firm - PR Newswire
Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) Seeking Recovery for Investors – Contact Levi & Korsinsky - GlobeNewswire
ZBIO Investors Have the Opportunity to Lead the Zenas BioPharma Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - GlobeNewswire
ZBIO Investor Reminder: Cohen Milstein Encourages Zenas - GlobeNewswire
ZBIO Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - marketscreener.com
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Morningstar
ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel - Bluefield Daily Telegraph
ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, - GlobeNewswire
Zenas Biopharma director Xiao Ting buys $77,600 in stock By Investing.com - Investing.com South Africa
The Gross Law Firm Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and ... - Bluefield Daily Telegraph
Zenas Biopharma director Xiao Ting buys $77,600 in stock - Investing.com
Zenas BioPharma, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before June 16, 2025 to Discuss Your RightsZBIO - Morningstar
Zenas BioPharma Investors Encouraged to Contact Cohen - GlobeNewswire
Zenas Biopharma Inc Stock (ZBIO) Financials Data
There is no financial data for Zenas Biopharma Inc (ZBIO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Zenas Biopharma Inc Stock (ZBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Xiao Ting | Director |
Feb 07 '25 |
Buy |
7.76 |
10,000 |
77,600 |
47,000 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 04 '24 |
Buy |
9.98 |
45,000 |
449,100 |
241,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 03 '24 |
Buy |
10.76 |
25,000 |
269,000 |
196,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 18 '24 |
Buy |
15.00 |
7,500 |
112,500 |
168,655 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 19 '24 |
Buy |
14.57 |
2,500 |
36,425 |
171,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 18 '24 |
Buy |
17.91 |
10,000 |
179,100 |
1,662,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 20 '24 |
Buy |
18.45 |
5,000 |
92,270 |
1,672,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 19 '24 |
Buy |
17.89 |
5,000 |
89,450 |
1,667,039 |
| Enavate Sciences GP, LLC | 10% Owner |
Sep 16 '24 |
Buy |
17.00 |
882,353 |
15,000,001 |
3,761,359 |
| Lu Hongbo | Director |
Sep 13 '24 |
Buy |
17.00 |
58,823 |
999,991 |
58,823 |
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):